Jove
Visualize
Contact Us

Related Experiment Videos

Dynamic tests and basal values for defining active acromegaly.

M Tzanela1

  • 1Department of Endocrinology, Diabetes and Metabolism, Evangelismos Hospital, Athens, Greece. mtzanel@med.uoa.gr

Neuroendocrinology
|October 19, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Ghrelin alterations during experimental and human sepsis.

Cytokine·2019
Same author

DKA cases over the last three years: has anything changed?

Diabetes & metabolic syndrome·2019
Same author

The Desmopressin Test Predicts Better Than Basal Cortisol the Long-Term Surgical Outcome of Cushing's Disease.

The Journal of clinical endocrinology and metabolism·2016
Same author

Economic Evaluation of Lanreotide Autogel in the Management of Acromegaly in Greece.

Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research·2016
Same author

Biochemical and clinical benefits of unilateral adrenalectomy in patients with subclinical hypercortisolism and bilateral adrenal incidentalomas.

European journal of endocrinology·2015
Same author

Abnormal Responsiveness to Dexamethasone-Suppressed CRH Test in Patients With Bilateral Adrenal Incidentalomas.

The Journal of clinical endocrinology and metabolism·2015
Same journal

Passive Smoking and Thyroid Diseases: Association by Mendelian Randomization Study.

Neuroendocrinology·2026
Same journal

Erratum.

Neuroendocrinology·2026
Same journal

Stress as a Neuroendocrine Modulator of the Reproductive Axis: Roles of Glucocorticoids, Kisspeptin and Serotonergic Signalling in Animal Models.

Neuroendocrinology·2026
Same journal

Pathological Classification and Clinical Characteristics of Growth Hormone-Secreting PitNETs.

Neuroendocrinology·2026
Same journal

Proximal-to-distal gradient and its implications in differentiation and prognosis in colorectal neuroendocrine neoplasms: the RGETNE-HERACLES study.

Neuroendocrinology·2026
Same journal

Inflammatory Signaling and Emotional Symptoms in Hashimoto's Thyroiditis Beyond Thyroid Function Status.

Neuroendocrinology·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Acromegaly diagnosis relies on growth hormone (GH) and insulin-like growth factor-I (IGF-I) levels. Measuring GH nadir during an oral glucose tolerance test and IGF-I levels helps confirm diagnosis and monitor treatment effectiveness.

Area of Science:

  • Endocrinology
  • Rare Diseases
  • Oncology

Background:

  • Acromegaly results from excess growth hormone (GH) secretion, typically due to a pituitary adenoma.
  • This oversecretion leads to increased morbidity and mortality through elevated GH and insulin-like growth factor-I (IGF-I) and tumor mass effects.
  • Diagnosis requires laboratory evaluation to confirm the condition.

Purpose of the Study:

  • To outline the diagnostic criteria for acromegaly.
  • To discuss the therapeutic goals for managing acromegaly.
  • To evaluate the reliability of GH nadir and IGF-I levels in assessing treatment efficacy.

Main Methods:

  • Diagnosis involves measuring random GH and IGF-I levels.
  • Oral glucose tolerance test (OGTT) is used to measure GH nadir (GHn) if initial tests are inconclusive.

Related Experiment Videos

  • Assessment of treatment efficacy involves monitoring both GHn and IGF-I levels.

    • Main Results:

    • Normal random GH (<0.4 microg/l) and IGF-I levels exclude acromegaly.
    • GHn <1 microg/l during OGTT also excludes acromegaly.
    • Biochemical control is defined by normalized age- and sex-adjusted IGF-I and GHn <1 microg/l during OGTT.

    Conclusions:

    • Both GHn and IGF-I levels are crucial for diagnosing and monitoring acromegaly.
    • There is ongoing debate regarding the relative reliability of GHn versus IGF-I in evaluating treatment success.
    • GHn and IGF-I may reflect different aspects of somatotrope function and disease activity.